Cancer Genomics & Proteomics,
Journal Year:
2023,
Volume and Issue:
20(4), P. 404 - 411
Published: Jan. 1, 2023
Targeted
therapy
has
become
increasingly
important
in
treating
lung
adenocarcinoma,
the
most
common
subtype
of
cancer.
Next-generation
sequencing
(NGS)
enables
precise
identification
specific
genetic
alterations
individual
tumor
tissues,
thereby
guiding
targeted
selection.
This
study
aimed
to
analyze
mutations
present
adenocarcinoma
tissues
using
NGS,
assess
benefit
and
evaluate
progress
availability
therapies
over
last
five
years.The
included
237
patients
treated
between
2018-2020.
The
Archer
FusionPlex
CTL
panel
was
used
for
NGS
analysis.Gene
variants
covered
by
were
detected
57%
fusion
genes
5.9%
patients.
At
time
study,
34
(14.3%
patients)
identified
with
a
targetable
variant.
Twenty-five
EGFR
variants,
8
EML4-ALK
one
patient
CD74-ROS1
received
therapy.
Prognosis
at
advanced
stages
tyrosine
kinase
inhibitors
alectinib
significantly
favorable
compared
without
any
variant
chemotherapy
(p=0.0172,
p=0.0096,
respectively).
Based
on
treatment
guidelines
applicable
May
2023,
number
who
could
profit
from
would
be
64
(27.0%
patients),
this
is
an
increase
88%
comparison
recommendations
valid
2018-2020.As
therapy,
assessment
mutational
profiles
crucial
approach
routine
management
oncological
Cancer Discovery,
Journal Year:
2024,
Volume and Issue:
14(9), P. 1675 - 1698
Published: May 7, 2024
First-generation
KRAS
G12C
inhibitors,
such
as
sotorasib
and
adagrasib,
are
limited
by
the
depth
duration
of
clinical
responses.
One
potential
explanation
for
their
modest
activity
is
dynamic
"cycling"
between
its
guanosine
diphosphate
(GDP)-
triphosphate
(GTP)-bound
states,
raising
controversy
about
whether
targeting
GDP-bound
form
can
fully
block
this
oncogenic
driver.
We
herein
report
that
D3S-001,
a
next-generation
inhibitor
with
faster
target
engagement
(TE)
kinetics,
depletes
cellular
active
at
nanomolar
concentrations.
In
presence
growth
factors,
epithelial
factor
hepatocyte
factor,
ability
adagrasib
to
inhibit
was
compromised
whereas
TE
kinetics
D3S-001
nearly
unaffected,
unique
feature
differentiating
from
other
inhibitors.
Furthermore,
high
covalent
potency
efficiency
contributed
robust
antitumor
preclinically
translated
into
promising
efficacy
in
an
ongoing
phase
1
trial
(NCT05410145).
Significance:
The
kinetic
study
presented
work
unveils,
first
time,
conformation-selective
potentially
deplete
factors
offers
new
insights
critical
features
drive
preclinical
class
drugs.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(3), P. 1025 - 1025
Published: Feb. 6, 2025
Non-small
cell
lung
carcinoma
(NSCLC)
comprises
the
majority
of
cancer
cases,
characterized
by
a
complex
interplay
genetic
alterations,
environmental
factors,
and
molecular
pathways
contributing
to
its
pathogenesis.
This
article
highlights
multifaceted
pathogenesis
NSCLC
discusses
screening
integrated
strategies
for
current
treatment
options.
is
an
evolving
field
with
various
aspects
including
underlying
oncogenic
driver
mutations,
immune
microenvironment
interactions
that
influence
tumor
progression
response
therapy.
Surgical
remains
most
applicable
curative
option,
especially
in
early
stages
disease,
adjuvant
chemotherapy
may
add
benefits
previously
resected
patients.
Combined
Radio-chemotherapy
can
also
be
used
palliative
purposes.
There
are
future
perspectives
advancing
horizons
management,
encompassing
novel
therapeutic
modalities
their
applications,
such
as
CAR-T
therapy,
antibody-drug
conjugates,
gene
therapies.
On
other
hand,
it’s
crucial
highlight
efficacy
innovative
Immunotherapy
checkpoint
inhibitors
nowadays
widely
NSCLC.
Moreover,
latest
advancements
profiling
techniques
development
targeted
therapies
designed
specific
alterations
play
significant
role
treatment.
In
conclusion,
personalized
approaches
cornerstone
successful
treatment,
they
based
on
patient’s
unique
profile,
characteristics,
host
factors.
Entitling
concept
individualized
requires
proper
patient
selection,
taking
into
consideration
mechanisms
resistance,
investigating
potential
combination
therapies,
achieve
optimal
impact
long-term
survival.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(4), P. 2044 - 2044
Published: Feb. 7, 2024
Brain
metastases
represent
a
significant
clinical
challenge
in
the
treatment
of
non-small-cell
lung
cancer
(NSCLC),
often
leading
to
severe
decline
patient
prognosis
and
survival.
Recent
advances
imaging
systemic
treatments
have
increased
detection
rates
brain
metastases,
yet
outcomes
remain
dismal
due
complexity
metastatic
tumor
microenvironment
(TME)
lack
specific
biomarkers
for
early
targeted
therapy.
The
intricate
interplay
between
NSCLC
cells
surrounding
TME
is
pivotal,
influencing
progression,
immune
evasion,
response
This
underscores
necessity
deeper
understanding
molecular
underpinnings
microenvironment,
identification
actionable
that
can
inform
multimodal
approaches.
goal
this
review
synthesize
current
insights
into
elucidate
mechanisms
metastases.
Furthermore,
we
will
explore
promising
horizon
emerging
biomarkers,
both
tissue-
liquid-based,
hold
potential
radically
transform
strategies
enhancement
outcomes.
Antioxidants and Redox Signaling,
Journal Year:
2024,
Volume and Issue:
41(4-6), P. 322 - 341
Published: March 6, 2024
Reactive
oxygen
species
(ROS)
are
generated
during
mitochondrial
oxidative
metabolism,
and
tightly
controlled
through
homeostatic
mechanisms
to
maintain
intracellular
redox,
regulating
growth
proliferation
in
healthy
cells.
However,
ROS
production
is
perturbed
cancers
where
abnormal
accumulation
of
leads
stress
genomic
instability,
triggering
oncogenic
signaling
pathways
on
one
hand,
while
increasing
damage
ROS-dependent
death
the
other.
Canadian Medical Association Journal,
Journal Year:
2024,
Volume and Issue:
196(16), P. E558 - E561
Published: April 28, 2024
KEY
POINTS
Lung
cancer
is
the
leading
cause
of
cancer-related
death
in
Canada,
with
non–small
cell
lung
carcinoma
(NSCLC)
making
up
85%
cases.[1][1]
has
been
associated
a
poor
prognosis,
particularly
for
patients
metastatic
disease.
Since
Health
Canada's
initial
approval
